A Randomized, Double Blind, Placebo Controlled, Ascending Single and Multiple Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Food Effect Study of RX-10001 in Healthy Volunteers.

Trial Profile

A Randomized, Double Blind, Placebo Controlled, Ascending Single and Multiple Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Food Effect Study of RX-10001 in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Nov 2014

At a glance

  • Drugs RX 10001 (Primary)
  • Indications Asthma; Inflammation
  • Focus Adverse reactions
  • Sponsors Resolvyx Pharmaceuticals
  • Most Recent Events

    • 03 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Jul 2009 Additional lead trial investigator (Renger Tiessen) identified, location (Netherlands) and official title added as reported by ClinicalTrials.gov.
    • 18 Jul 2009 Planned end date (Sep 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top